IBRX Operating Cash Flow (Statement)
Immunitybio Inc · Operating Cash Flow (Statement)
IBRX Operating Cash Flow (Statement)
Latest reported-$281.14Mperiod ending
IBRX TTM Cash from Operations (-$5.35M → -$281.14M)
TTM operating cash flow (statement)
High-resolution chart · PNG
IBRX operating cash flow (statement) history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Operating Cash Flow (Statement) (USD) |
|---|---|
| -281,138,000 | |
| -294,390,000 | |
| -304,936,000 | |
| -319,702,000 | |
| -349,558,000 | |
| -370,159,000 | |
| -391,236,000 | |
| -421,363,000 | |
| -410,003,000 | |
| -389,429,000 | |
| -366,757,000 | |
| -342,213,000 | |
| -335,410,000 | |
| -346,889,000 | |
| -337,509,000 | |
| -318,421,000 | |
| -310,537,000 | |
| -288,880,000 | |
| -274,419,000 | |
| -260,384,000 | |
| -224,659,000 | |
| -201,086,000 | |
| -171,724,000 | |
| -129,005,000 | |
| -108,586,000 | |
| -79,391,000 | |
| -61,362,000 | |
| -60,510,000 | |
| -61,509,000 | |
| -60,948,000 | |
| -63,381,000 | |
| -62,988,000 | |
| -55,550,000 | |
| -54,234,000 | |
| -48,780,000 | |
| -45,893,000 | |
| -46,443,000 | |
| -39,794,000 | |
| -38,593,000 | |
| -38,925,000 | |
| -32,420,000 | |
| -26,840,000 | |
| -25,305,000 | |
| -16,776,000 | |
| -13,303,000 | |
| -12,584,000 | |
| -5,354,000 |